SWX:SDZPharmaceuticals
Sandoz Group (SWX:SDZ) Looks Fully Valued After Henlius Biosimilar Deal
Sandoz Group (SWX:SDZ) is back in focus after the company agreed a collaboration with Shanghai Henlius Biotech to develop, manufacture and commercialise up to 10 biosimilars, with milestone payments up to US$322 million.
See our latest analysis for Sandoz Group.
The collaboration news arrives as Sandoz Group trades at CHF73.84, with a 30 day share price return of 15.45% and a year to date share price return of 29.05%. Over the past year, total shareholder return of 48.82% indicates that...